Owing to the development of multiple novel therapies, there has been major progress in the
treatment of advanced prostate cancer over the last two decades; however, the disease …

Patients with high-risk prostate cancer treated with curative intent are at an increased risk of
biochemical recurrence, metastatic progression and cancer-related death compared with …

The genomics of primary prostate cancer differ from those of metastatic castration-resistant
prostate cancer (mCRPC). We studied genomic aberrations in primary prostate cancer …

Background Several systemic therapeutic options exist for metastatic castrate-sensitive
prostate cancer (mCSPC). Circulating tumor DNA (ctDNA) can molecularly profile metastatic …

Background In the PREVAIL study, enzalutamide significantly improved clinical outcomes
versus placebo in patients with chemotherapy-naïve metastatic castration-resistant prostate …

The release of circulating tumor cells (CTCs) into vasculature is an early event in the
metastatic process. The analysis of CTCs in patients has recently received widespread …

Prostate cancer is the most frequent nonskin cancer and second most common cause of
cancer-related deaths in man. Prostate cancer is a clinically heterogeneous disease with …

Circulating tumor DNA (ctDNA) enables real-time genomic profiling of cancer without the
need for tissue biopsy. ctDNA-based technology is seeing rapid uptake in clinical practice …

Context Genomic stratification can impact prostate cancer (PC) care through diagnostic,
prognostic, and predictive biomarkers that aid in clinical decision-making. The temporal and …

Background Metastatic prostate cancer is a clonally heterogeneous disease state
characterized by progressive somatic perturbations. The aim of this study was to identify cell …